Estimating required information size by quantifying diversity in random-effects model meta-analyses

Jørn Wetterslev, Kristian Thorlund, Jesper Brok, Christian Gluud, Jørn Wetterslev, Kristian Thorlund, Jesper Brok, Christian Gluud

Abstract

Background: There is increasing awareness that meta-analyses require a sufficiently large information size to detect or reject an anticipated intervention effect. The required information size in a meta-analysis may be calculated from an anticipated a priori intervention effect or from an intervention effect suggested by trials with low-risk of bias.

Methods: Information size calculations need to consider the total model variance in a meta-analysis to control type I and type II errors. Here, we derive an adjusting factor for the required information size under any random-effects model meta-analysis.

Results: We devise a measure of diversity (D2) in a meta-analysis, which is the relative variance reduction when the meta-analysis model is changed from a random-effects into a fixed-effect model. D2 is the percentage that the between-trial variability constitutes of the sum of the between-trial variability and a sampling error estimate considering the required information size. D2 is different from the intuitively obvious adjusting factor based on the common quantification of heterogeneity, the inconsistency (I2), which may underestimate the required information size. Thus, D2 and I2 are compared and interpreted using several simulations and clinical examples. In addition we show mathematically that diversity is equal to or greater than inconsistency, that is D2 >or= I2, for all meta-analyses.

Conclusion: We conclude that D2 seems a better alternative than I2 to consider model variation in any random-effects meta-analysis despite the choice of the between trial variance estimator that constitutes the model. Furthermore, D2 can readily adjust the required information size in any random-effects model meta-analysis.

Figures

Figure 1
Figure 1
Diversity (D2) compared to inconsistency (I2) in 10,000 simulations of meta-analyses with number of trials included k = 6. Odds ratio = 1.00 and proportion of events in control group PC = 0.30. Meta-analyses depicted as open circles. D2 nears asymptotically to I2 when heterogeneity nears 0% or 100%. Line of unity, D2 = I2 black line.
Figure 2
Figure 2
Diversity (D2) compared to inconsistency (I2) in 10,000 simulations of meta-analyses with number of trials included k = 20. Odds ratio = 0.70 and proportion of events in control group PC = 0.30. Meta-analyses depicted as open circles. D2 nears asymptotically to I2 when heterogeneity nears 0% or 100%. Line of unity, D2 = I2 black line.
Figure 3
Figure 3
Diversity (D2) in % compared to inconsistency (I2) in % in seven meta-analyses (see Table 1) depicted as open circles. The open circles indicate that D2 is always equal to or larger than I2. 100% heterogeneity is impossible and the upper right point is just to illustrate that D2 nears asymptotically to I2 when heterogeneity nears 100%. Line of unity, D2 = I2 is the dotted blue line.

References

    1. Guyatt GH, Mills EJ, Elbourne D. In the era of systematic reviews, does the size of an individual trial still matter? PLoS Medicine. 2008;5(1):e4. doi: 10.1371/journal.pmed.0050004. doi:10.1371/jounal.pmed.0050004.
    1. Pogue J, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clinical Trials. 1997;18:580–93. doi: 10.1016/S0197-2456(97)00051-2.
    1. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet. 1998;351(9095):47–52. doi: 10.1016/S0140-6736(97)08461-4.
    1. Devereaux PJ, Beattie WS, Choi PT, Badner NH, Guyatt GH, Villar JC. How strong is the evidence for the use of perioperative beta-blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ. 2005;331(7512):313–21. doi: 10.1136/bmj.38503.623646.8F.
    1. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in a meta-analysis. Journal of Clinical Epidemiology. 2008;61(1):64–75. doi: 10.1016/j.jclinepi.2007.03.013.
    1. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology. 2008;61(8):763–9. doi: 10.1016/j.jclinepi.2007.10.007.
    1. Thorlund K, Devereaux PJ, Wetterslev, Guyatt G, Ioannidis JPA, Thabane L, Gluud LL, Als-Nielsen B, Gluud C. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? International Journal of Epidemiology. 2008. Doi:10.1093/iej/dyn179.
    1. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive-Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology. 2008. Doi:10.1093/iej/dyn188.
    1. Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Medical Research Methodology. 2002;2:3. doi: 10.1186/1471-2288-2-3.
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine. 2002;21:1539–1558. doi: 10.1002/sim.1186.
    1. Feinstein AR. Clinical Epidemiology: the Architecture of Clinical Research. Philadelphia: W.B. Saunders; 1985. p. 166.
    1. Chow S-C, Shao J, Wang H. In: Sample Size Calculation in Clinical Research. Shein-Chung Chow, editor. Chapter 8.8.1. CRC, Taylor & Francis Group; 2003. pp. 204–206.
    1. Spiegel MR. Mathematical Handbook of Formulas and Tables. Schaum's outline series, McGraw-Hill Book Company; 1971.
    1. Takouche B, Cadarso-Suaréz C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. American Journal of Epidemiology. 1999;150:206–215.
    1. DerSimonian R, Laird NM. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2.
    1. Afshari A, Wetterslev J, Brok J, Møller AM. Antithrombin III in critically ill patients. A systematic review with meta-analysis and trial sequential analysis. BMJ. 2007;335(7632):1219–20. doi: 10.1136/bmj.39398.682500.25.
    1. Al-Inany HG, Abou-Settea AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database of Systematic Reviews. 2006;3:CD001750.
    1. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. The Cochrane Database of Systematic Reviews. 1997;4:CD000511. 10.1002/14651858. C.
    1. Wetterslev J, Juul AB. Benefits and harms of perioperative beta-blockade. Best Practice and Research of Clinical Anesthesiology. 2006;20:285–302. doi: 10.1016/j.bpa.2005.10.006.
    1. Bury RG, Tudehope D. Enteral antibiotics for preventing necrotizing enterocolitis in low birthweight or preterm infants. The Cochrane Database of Systematic Reviews. 2000;2:CD000405. DOI: 10.1002/14651858.CD000405.
    1. Li J, Zhang M, Egger M. Intravenous magnesium for acute myocardial infarction. Cochrane Database of Systematic Reviews. 2007;2:CD002755.
    1. Meyhoff CS, Wetterslev J, Jorgensen LN, Henneberg SW, Simonsen I, Pulawska T, Walker LR, Skovgaard N, Heltø K, Gocht-Jensen P, Carlsson PS, Rask H, Karim S, Carlsen CG, Jensen FS, Rasmussen LS. the PROXI Trial Group. Perioperative oxygen fraction - effect on surgical site infection and pulmonary complications after abdominal surgery: a randomized clinical trial. Rationale and design of the PROXI-Trial. Trials. 2008;9(1):58. doi: 10.1186/1745-6215-9-58.
    1. Gluud LL. Bias in clinical intervention research. American Journal of Epidemiology. 2006;163:493–501. doi: 10.1093/aje/kwj069.
    1. Chan AW, Hrobjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. Journal of American Medical Association. 2004;291(20):2457–2465. doi: 10.1001/jama.291.20.2457.
    1. Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ. 2005;330(7494):753. doi: 10.1136/bmj.38356.424606.8F.
    1. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336(7644):601–5. doi: 10.1136/.
    1. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Guyatt G. Randomized trials stopped early for benefit: a systematic review. Journal of American Medical Association. 2005;294(17):2203–2209. doi: 10.1001/jama.294.17.2203.
    1. Flather MD, Farkouh ME, Pogue JM, Yusuf S. Strengths and limitations of meta-analysis: larger studies may be more reliable. Controlled Clinical Trials. 1997;18(6):568–579. doi: 10.1016/S0197-2456(97)00024-X.
    1. Fedorov V, Jones B. The design of multicentre trials. Statistical Methods in Medical Research. 2005;14:205–248. doi: 10.1191/0962280205sm399oa.
    1. Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet. 2008;372(9654):1962–76. doi: 10.1016/S0140-6736(08)61560-3.
    1. Jennison C, Turnbull BW. Group sequential methods with application to clinical trials. Chapter III. Chapman & Hall/CRC; 2000. p. 49.
    1. Sidik K, Jonkman JN. A comparison of heterogeneity variance estimators in combining results of studies. Statistics in Medicine. 2007;30;26(9):1964–81. doi: 10.1002/sim.2688.
    1. Rücker G, Schwarzer, Carpenter JR, Schumacher M. Undue reliance on I 2 in assessing heterogeneity may mislead. BMC Medical Research Methodology. 2008;8:79. doi: 10.1186/1471-2288-8-79. doi:10.1186/1471-2288-8-79.
    1. Higgins JP. Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. International Journal of Epidemiology. 2008;37:1158–1160. doi: 10.1093/ije/dyn204.
    1. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Are large trials less reliable than small trials? Letter to the editor. Journal of Clinical Epidemiology. 2009;62:886–889. doi: 10.1016/j.jclinepi.2009.03.007.
    1. Ioannidis JP, Trikalinos TA, Zintzaras E. Extreme between-study homoge-neity in meta-analyses could offer useful insights. Journal of Clinical Epidemiology. 2006;59(10):1023–32. doi: 10.1016/j.jclinepi.2006.02.013.
    1. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007;335(7626):914–6. doi: 10.1136/bmj.39343.408449.80.

Source: PubMed

3
購読する